NCT01667562View on ClinicalTrials.gov

A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

375

Participants

Timeline

Start Date

January 20, 2012

Primary Completion Date

September 7, 2017

Study Completion Date

September 7, 2017

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Erlotinib

Daily oral doses administered until disease progression or unacceptable toxicity or death.

Trial Locations (4)

11000

Clinic for Pulmonology, Clinical Center of Serbia, Belgrade

11080

Clinical Center Bezanijska Kosa; Oncology, Belgrade

21204

Institute for pulmonary diseases of Vojvodina, Kamenitz

Unknown

Clinical Center Nis; Clinic for pulmonary diseases Knez Selo, Niš

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01667562 - A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter